My Treatment Approach: Improving Chronic Lymphocytic Leukemia Management and Treatment Outcomes

A panel of experts on chronic lymphocytic leukemia (CLL) review a patient case and describe their initial impressions on treatment decisions.

Bita Fakhri, MD, MPH, outlines factors she considers when choosing between fixed-duration and continuous BTK inhibitor therapy and discusses how she approaches treatment discussions with patients.

John N. Allan, MD, describes how he selects patients for first-line treatment with continuous BTK inhibitor therapy, referencing data from the RESONATE-2, ELEVATE-TN, and SEQUOIA studies.

Catherine C. Coombs, MD, discusses the value of real-world data in informing the treatment of patients with chronic lymphocytic leukemia.

Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.

Experts on chronic lymphocytic leukemia detail how clinical trial data on doublet therapies help inform treatment decisions in the first line.

Bita Fakhri, MD, MPH, discusses the importance of patient involvement in the shared decision-making process to individualize treatment and improve outcomes.

John N. Allan, MD, provides clinical insights on how appropriate dose ramp-up practices for venetoclax can minimize adverse events and optimize patient outcomes.

Catherine C. Coombs, MD, outlines considerations for long-term treatment planning, particularly in younger patients with chronic lymphocytic leukemia.

A hematology and oncology specialist presents the case of a 66-year-old man with chronic lymphocytic leukemia.

Experts on chronic lymphocytic leukemia discuss treatment practices for patients with relapsed/refractory CLL and provide insights on the role for venetoclax in patients who previously received BTK inhibitors.

The panel addresses the intricacies of treating patients with chronic lymphocytic leukemia who experience treatment resistance.

Bita Fakhri, MD, MPH, shares her general approach to managing common cardiovascular adverse events associated with BTK inhibitors in patients with chronic lymphocytic leukemia.

Highlighting recent clinical trial data on pirtobrutinib in patients with chronic lymphocytic leukemia, the panel shares their experience utilizing it in clinical practice.

The panel concludes its discussion with a look to the future of CLL treatment, focusing on emerging novel agents and exciting clinical research.